Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of XmAb27564 in Healthy Volunteers
NCT04857866Phase 1Completed
- Sponsor
- Xencor
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Fc Fusion Proteins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases comparing XmAb27564 Arm with Placebo Arm (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2021; status: completed.
02
Drugs
XmAb564
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT04857866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857866.